Repligen Corp (RGEN) — 8-K Filings

8-K Filings (16)

• 8-K Filing — May 5, 2026
• Repligen Corp. Files 8-K on Financials — Oct 28, 2025 Risk: low
  Repligen Corp. filed an 8-K on October 28, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and ex
• Repligen Corp Files 8-K on Officer/Director Changes — Sep 2, 2025 Risk: medium
  Repligen Corporation filed an 8-K on September 2, 2025, reporting events as of September 1, 2025. The filing indicates changes related to the departure of direc
• Repligen Corp Files 8-K on Financials — Jul 29, 2025 Risk: low
  Repligen Corporation filed an 8-K on July 29, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and
• Repligen Corp Files 8-K with Corporate Updates — May 15, 2025 Risk: low
  Repligen Corporation filed an 8-K on May 15, 2025, reporting on several key items. These include amendments to its articles of incorporation or bylaws, the subm
• Repligen Corp Files 8-K on Financials — Feb 20, 2025 Risk: low
  Repligen Corporation filed an 8-K on February 20, 2025, reporting on its results of operations and financial condition. The filing includes financial statements
• Repligen Corp Files 8-K on Financials — Nov 12, 2024 Risk: low
  Repligen Corporation filed an 8-K on November 12, 2024, to report on its results of operations and financial condition. The filing also includes Regulation FD d
• Repligen Corp. Restates Financials Amid Investigation — Sep 18, 2024 Risk: high
  Repligen Corporation announced on September 12, 2024, that it will not rely on previously issued financial statements or related audit reports due to an ongoing
• Repligen Corp Files 8-K on Operations and Financials — Jul 30, 2024 Risk: low
  Repligen Corporation filed an 8-K on July 30, 2024, reporting on its results of operations and financial condition, and including financial statements and exhib
• Repligen Acquires Validus Therapeutics for $100M+ — Jul 15, 2024 Risk: medium
  Repligen Corporation announced on July 15, 2024, that it has entered into a definitive agreement to acquire Validus Therapeutics, a privately held company, for
• Repligen Corp Appoints New CFO, Elects Directors — Jun 14, 2024 Risk: medium
  Repligen Corporation announced on June 12, 2024, changes in its executive team. Effective June 12, 2024, Catherine M. Davis was appointed as the new Chief Finan
• Repligen to Acquire Izon Science for $113M — Jun 13, 2024 Risk: medium
  Repligen Corporation announced on June 13, 2024, that it has entered into a definitive agreement to acquire Izon Science Ltd. for approximately $113 million. Th
• Repligen Corp Files 8-K on Shareholder Vote Matters — May 17, 2024 Risk: low
  Repligen Corporation filed an 8-K on May 17, 2024, reporting on matters submitted to a vote of security holders on May 16, 2024. The filing does not disclose th
• Repligen Corp Files 8-K on Financials — May 1, 2024 Risk: low
  Repligen Corporation filed an 8-K on May 1, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and e
• Repligen Corp Elects Dr. Jonathan M. Rothberg to Board — Mar 19, 2024 Risk: low
  Repligen Corporation announced on March 18, 2024, that its Board of Directors has elected Dr. Jonathan M. Rothberg as a Class II director, effective immediately
• Repligen Files 8-K on Financial Condition and Operations — Feb 21, 2024 Risk: low
  Repligen Corporation filed an 8-K on February 21, 2024, reporting on its results of operations and financial condition. The filing indicates that the company, b

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX